BG Pulse Journal USA

ISSN:1947-2536 http://www.bgpulseusa.com/index.php/bg

EFFECT OF COMPREHENSIVE PHARMACOTHERAPY ON CLINICAL OUTCOMES IN CHRONIC HEART FAILURE

Raximova Dilorom Orifjonovna

Associate Professor, Department of Pharmacognosy and Drug Standardization, Tashkent Pharmaceutical Institute, Uzbekistan.

Email: rahimovadilorom644@gmail.com

ORCID: https://orcid.org/0009-0009-9767-0898

Rustamov Ibrahim Xudoyberdiyevich

Senior Lecturer, Department of Pharmacognosy and Drug Standardization, Tashkent Pharmaceutical Institute, Uzbekistan.

Email: ibrokhim.rustamov.60@mail.ru

ORCID: https://orcid.org/0009-0009-6776-0998

Nurmatov Shavkat Ubaydullayevich

Assistant Lecturer, Department of Pharmacognosy and Drug Standardization, Tashkent Pharmaceutical Institute, Uzbekistan.

Email: savkatzon89@gmail.com

ORCID: https://orcid.org/0049-0085-9767-0798

Abstract: Background: Chronic heart failure (CHF) remains associated with hospitalization, functional limitation and premature mortality. Objective: To evaluate how evidence-based combination pharmacotherapy influences clinical outcomes and to identify implementation barriers. Methods: A structured narrative synthesis of pivotal randomized trials, international guidelines and relevant Uzbekistan health-system guidance was performed; no original patient cohort was enrolled. Results: Four foundational drug classes constitute guideline-directed therapy for heart failure with reduced ejection fraction (HFrEF). In DAPA-HF, the primary outcome occurred in 16.3% receiving dapagliflozin versus 21.2% on placebo; in EMPEROR-Reduced, corresponding proportions were 19.4% versus 24.7%. These outcomes reflect different trial populations and follow-up durations. Tolerability, renal function, potassium, blood pressure and access influence implementation. Conclusion: Early initiation, individualized titration and monitoring of complementary therapies

improve outcomes in eligible patients, whereas findings must be distinguished by ejection fraction phenotype.

Keywords: chronic heart failure; guideline-directed medical therapy; SGLT2 inhibitor; angiotensin receptor–neprilysin inhibitor; hospitalization; mortality.

INTRODUCTION

Chronic heart failure is a progressive syndrome caused by structural or functional cardiac abnormalities that elevate intracardiac pressures or impair cardiac output. Its health burden extends beyond mortality to repeated admissions, high costs, limited exercise tolerance and loss of productivity. Clinical classification by left-ventricular ejection fraction distinguishes HFrEF (≤40%), HF with mildly reduced ejection fraction (41–49%) and HF with preserved ejection fraction (≥50%). Because efficacy differs between phenotypes, a treatment review that treats all heart failure as a single population may be misleading [1, 2].

The modern paradigm for HFrEF combines renin–angiotensin system inhibition (preferably an ARNI when appropriate), evidence-based beta-blockade, mineralocorticoid receptor antagonism and SGLT2 inhibition. These agents affect complementary biological pathways, including maladaptive neurohormonal activation, sodium handling, ventricular remodeling and myocardial energetics. Loop diuretics remain important for congestion relief, but their principal benefit is symptomatic rather than clearly established survival improvement [1, 3].

In Uzbekistan, medication availability, referral pathways, affordability, and continuity between outpatient and inpatient cardiology services are important practical considerations. The objective of this paper is to synthesize verified evidence on comprehensive CHF pharmacotherapy and provide an applicable clinical-monitoring framework, while separating trial results from local extrapolation.

LITERATURE REVIEW

The 2022 American guideline and 2023 ESC focused update support a multi-class treatment strategy, while assigning phenotype-specific priorities. For HFrEF, quadruple therapy is central. For mildly reduced and preserved ejection fraction, SGLT2 inhibitors have particularly strong evidence for reducing the combined risk of cardiovascular death or heart-failure hospitalization; benefits on individual mortality endpoints are less consistent [1, 2].

PARADIGM-HF established sacubitril/valsartan superiority to enalapril for a cardiovascular-death-or-HF-hospitalization composite in symptomatic HFrEF. DAPA-HF and EMPEROR-Reduced subsequently demonstrated favorable outcomes when SGLT2 inhibitors were added to background treatment [4–6]. In patients with an ejection fraction above 40%, DELIVER and EMPEROR-Preserved extended evidence for SGLT2 inhibition, with a major contribution from reduced worsening-HF events [7, 8].

STRONG-HF highlighted the value of a structured strategy involving prompt initiation, rapid up-titration and close early follow-up after hospitalization. This does not imply that rapid intensification is safe without clinical or laboratory supervision; potassium, renal function, hypotension, bradycardia and volume status must shape an individualized plan [9]. Local

implementation should be consistent with Uzbekistan's nationally approved clinical care pathways and medicines regulation [10].

MATERIALS AND METHODS

Study design. This article is a structured narrative review and evidence synthesis, not a prospective trial, retrospective chart review or meta-analysis. Sources comprised peer-reviewed pivotal randomized controlled trials, professional-society guidelines and a local regulatory resource. The literature was screened for relevance to adult chronic heart failure, therapies with established clinical endpoints, and risk-management implications. Comparisons emphasize randomized allocation, comparator regimens, sample sizes, follow-up, hazard ratios and reported absolute event proportions.

The primary outcomes of interest were cardiovascular death and worsening heart failure or hospitalization; secondary themes included all-cause mortality, symptoms, quality of life, renal events and treatment tolerability. Reported values were preserved as published and not combined statistically because populations, trial endpoints and follow-up periods differ. Absolute risk differences are descriptive within each trial and must not be interpreted as a cross-trial ranking of drugs. No fabricated local patient data, statistical significance tests or new hazard ratios were generated.

Table 1. Therapeutic pillars and implementation priorities in HFrEF

Drug class	**Clinical role**	**Monitoring / practical considerations**
ARNI / ACE inhibitor / ARB	Reduces neurohormonal injury; ARNI preferred in eligible symptomatic HFrEF	Blood pressure, creatinine, potassium; ARNI/ACE-inhibitor washout
Evidence-based beta-blocker	Reduces adrenergic activation and adverse outcomes	Heart rate, blood pressure, congestion, tolerance
Mineralocorticoid antagonist	Reduces adverse outcomes in eligible HFrEF	Serum potassium and renal function
SGLT2 inhibitor	Reduces HF worsening and HF hospitalizations	Volume status, renal function; infection and ketoacidosis precautions
Loop diuretic	Relieves fluid retention and congestion	Weight, edema, electrolytes, kidney function

Interpretation of Table 1: The first four rows represent disease-modifying classes for eligible HFrEF patients; the diuretic row represents symptom-directed decongestion. Initiation and titration should reflect the patient's clinical profile rather than a rigid sequence [1, 2].

RESULTS

Across the evaluated evidence, comprehensive pharmacotherapy consistently improved clinically meaningful outcomes relative to control regimens within major randomized studies. In DAPA-HF, 4,744 patients with symptomatic HFrEF were randomized to dapagliflozin or placebo on top of guideline-recommended therapy. Over a median 18.2 months, the trial-specific primary outcome

occurred in 16.3% versus 21.2% (hazard ratio 0.74; 95% CI 0.65–0.85). The within-trial absolute difference was 4.9 percentage points [5].

EMPEROR-Reduced enrolled 3,730 patients with HFrEF and compared empagliflozin with placebo added to background care. Over a median 16 months, the primary composite endpoint occurred in 19.4% versus 24.7% (hazard ratio 0.75; 95% CI 0.65–0.86); the within-trial difference was 5.3 percentage points [6]. These results cannot be pooled merely by averaging displayed percentages.

Table 2. Selected randomized trial findings (trial-specific outcomes)

Study	Population / comparator	Primary endpoint: treatment vs control	Hazard ratio
DAPA-HF [5]	HFrEF; dapagliflozin vs placebo	16.3% vs 21.2%	0.74
EMPEROR-Reduced [6]	HFrEF; empagliflozin vs placebo	19.4% vs 24.7%	0.75
PARADIGM-HF [4]	HFrEF; sacubitril/valsartan vs enalapril	CV death / HF hospitalization composite	0.80
DELIVER [7]	LVEF >40%; dapagliflozin vs placebo	Worsening HF / CV death composite	0.82

Table 2 compares findings as originally reported. Percentages are given only where extracted from the respective trials; endpoints for PARADIGM-HF and DELIVER are listed without inventing a common absolute outcome percentage. Differences in study population, follow-up and composite endpoint definitions limit direct comparisons [4–7].

Figure 1. Primary endpoint event proportions in two separate HFrEF trials





Figure 1 illustrates the direction of benefit from SGLT2 inhibition in each trial against its own placebo-treated population. The plotted event proportions should not be mistaken for a single pooled trial or a direct randomized comparison between dapagliflozin and empagliflozin. A clinically useful interpretation is that adding an SGLT2 inhibitor to standard care lowers the

probability of worsening heart failure and selected cardiovascular outcomes in eligible HFrEF [5, 6].

Figure 2. Hazard ratios for distinct primary endpoints from pivotal studies



All hazard ratios plotted in Figure 2 favor active treatment, but they refer to different control regimens and occasionally different endpoints; they are not a comparative drug-efficacy ranking. The graphical reference at 1.0 signifies no treatment-control difference. The values support the broader concept of evidence-based multi-pathway treatment rather than interchangeable treatment choices [4–7].

DISCUSSION

The clinical significance of comprehensive CHF pharmacotherapy derives from additive, complementary disease mechanisms. In HFrEF, combining therapies allows clinicians to interrupt neurohormonal and cardiorenal pathways concurrently. However, the magnitude of benefit in a given individual depends on baseline risk, disease severity, age, kidney function, comorbid conditions, adherence and the actual doses achieved. Recommendations should therefore encourage early use of all appropriate pillars followed by careful optimization, without assuming every patient can tolerate every class [1, 2].

Symptomatic gains and prevention of admission have a direct bearing on healthcare utilization. Reduced readmissions may support better patient functioning, but economic benefits cannot be claimed for Uzbekistan without local cost-effectiveness data. Hospital discharge planning should include medication reconciliation, evaluation of contraindications, an understandable treatment plan, and an early follow-up appointment. Structured dose titration with renal and electrolyte surveillance helps detect safety problems before they cause discontinuation [9, 10].

The preserved-ejection-fraction population requires caution: results established for HFrEF are not automatically transferable to HFpEF. Contemporary evidence does support SGLT2 inhibitors across a broader EF range, but therapeutic decisions also require treatment of hypertension, atrial fibrillation, obesity, chronic kidney disease and congestion [2, 7, 8]. Overgeneralization of all-cause or cardiovascular mortality benefits would misrepresent outcomes driven chiefly by fewer heart-failure hospitalizations in some preserved-EF trials.

Important adverse effects include hypotension and renal-function fluctuation during renin–angiotensin system modulation, hyperkalemia with mineralocorticoid antagonism, fatigue or bradycardia with beta-blockers, and volume depletion or rare ketoacidosis with SGLT2 inhibitors. An individualized clinical pathway must balance these problems against undertreatment. Patients should receive advice concerning daily weight tracking, alarm symptoms, medication adherence, and when to seek urgent evaluation.

Limitations. This evidence synthesis is narrative and is vulnerable to selective inclusion. The studies differ in entry criteria, outcome definitions and follow-up, precluding numerical pooling here. No original Uzbekistan patient cohort was collected, and no local efficacy estimate or treatment-cost estimate is claimed. Future multicenter studies in Uzbekistan should measure prescribing rates of the four HFrEF pillars, adherence, NYHA class, NT-proBNP, hospitalization, mortality, renal safety and longitudinal quality of life.

CONCLUSION

Comprehensive guideline-directed pharmacotherapy is associated with better clinical outcomes among eligible adults with chronic HFrEF. The combined approach integrates a renin–angiotensin pathway inhibitor, evidence-based beta-blocker, mineralocorticoid antagonist and SGLT2 inhibitor, while diuretics address congestion. Randomized trials demonstrate meaningful reductions in worsening-heart-failure composites with SGLT2 inhibitors; interpretation of mortality benefits must remain outcome- and phenotype-specific. Safe clinical adoption requires systematic monitoring, patient education and continuity of care. Local prospective evidence is needed to evaluate real-world effectiveness in Uzbekistan.

REFERENCES:

1. Heidenreich, P. A., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012
2. McDonagh, T. A., et al. (2023). 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 44(37), 3627–3639. https://doi.org/10.1093/eurheartj/ehad195
3. McDonagh, T. A., et al. (2021). 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(36), 3599–3726. https://doi.org/10.1093/eurheartj/ehab368
4. McMurray, J. J. V., et al. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371, 993–1004. https://doi.org/10.1056/NEJMoa1409077
5. McMurray, J. J. V., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, 1995–2008. https://doi.org/10.1056/NEJMoa1911303
6. Packer, M., et al. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383, 1413–1424. https://doi.org/10.1056/NEJMoa2022190

7. Solomon, S. D., et al. (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine, 387, 1089–1098. https://doi.org/10.1056/NEJMoa2206286
8. Anker, S. D., et al. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385, 1451–1461. https://doi.org/10.1056/NEJMoa2107038
9. Mebazaa, A., et al. (2022). Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF). The Lancet, 400(10367), 1938–1952. https://doi.org/10.1016/S0140-6736(22)02076-1
10. Ministry of Health of the Republic of Uzbekistan. (n.d.). Official healthcare information and national clinical guidance portal. https://gov.uz/ssv (Accessed October 16, 2026).